Real-world Evidence on Levodopa Dose Escalation in Patients with Parkinson's Disease Treated with Istradefylline

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Dec 22

PMID 38134023

Authors

Nobutaka Hattori

Daijiro Kabata

Shinji Asada

Tomoyuki Kanda

Takanobu Nomura

Ayumi Shintani

Akihisa Mori

Affiliations

Soon will be listed here.

Abstract

Objective: Istradefylline, a selective adenosine A2A receptor antagonist, is indicated in the US and Japan as adjunctive treatment to levodopa/decarboxylase inhibitors in adults with Parkinson's disease (PD) experiencing OFF time. This study aimed to observe patterns of dose escalation of levodopa over time in patients initiated on istradefylline.

Methods: Using Japanese electronic health record data, interrupted time series analyses were used to compare levodopa daily dose (LDD, mg/day) gradients in patients before and after initiation of istradefylline. Data were analyzed by period relative to istradefylline initiation (Month 1): pre-istradefylline (Months -72 to 0), early istradefylline (Months 1 to 24), and late istradefylline (Months 25 to 72). Subgroup analyses included LDD before istradefylline initiation (<400, ≥400 to <600, ≥600 mg/day) and treatment with or without monoamine oxidase-B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, or dopamine agonists before istradefylline initiation.

Results: The analysis included 4026 patients; mean (SD) baseline LDD was 419.27 mg (174.19). Patients receiving ≥600 mg/day levodopa or not receiving MAO-B inhibitors or COMT inhibitors demonstrated a significant reduction in LDD increase gradient for pre-istradefylline vs late-phase istradefylline (≥600 mg/day levodopa, -6.259 mg/day each month, p<0.001; no MAO-B inhibitors, -1.819 mg/day each month, p = 0.004; no COMT inhibitors, -1.412 mg/day each month, p = 0.027).

Conclusions: This real-world analysis of Japanese prescription data indicated that slowing of LDD escalation was observed in patients initiated on istradefylline, particularly in those receiving ≥600 mg/day levodopa, suggesting istradefylline may slow progressive LDD increases. These findings suggest that initiating istradefylline before other levodopa-adjunctive therapies may mitigate LDD increases, potentially reducing occurrence or severity of levodopa-induced complications in long-term istradefylline treatment.

References

Fahn S . Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol. 2005; 252 Suppl 4:IV37-IV42. DOI: 10.1007/s00415-005-4008-5. View

Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P . The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015; 766:25-30. DOI: 10.1016/j.ejphar.2015.09.028. View

Muller T, Kuhn W . Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord. 2009; 24(9):1339-43. DOI: 10.1002/mds.22607. View

Hauser R, Hattori N, Fernandez H, Isaacson S, Mochizuki H, Rascol O . Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021; 11(4):1663-1675. PMC: 8609697. DOI: 10.3233/JPD-212672. View

Muller T . Catechol-O-methyltransferase inhibitors in Parkinson's disease. Drugs. 2015; 75(2):157-74. DOI: 10.1007/s40265-014-0343-0. View

Wagner A, Soumerai S, Zhang F, Ross-Degnan D . Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309. DOI: 10.1046/j.1365-2710.2002.00430.x. View

Muller T . The role of istradefylline in the Parkinson's disease armamentarium. Expert Opin Pharmacother. 2023; 24(7):863-871. DOI: 10.1080/14656566.2023.2201374. View

Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M . Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 2003; 61(3):293-6. DOI: 10.1212/01.wnl.0000073136.00548.d4. View

Politis M, Wilson H, Wu K, Brooks D, Piccini P . Chronic exposure to dopamine agonists affects the integrity of striatal D receptors in Parkinson's patients. Neuroimage Clin. 2017; 16:455-460. PMC: 5577411. DOI: 10.1016/j.nicl.2017.08.013. View

10.

Fearnley J, Lees A . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114 ( Pt 5):2283-301. DOI: 10.1093/brain/114.5.2283. View

11.

Rahmim A, Salimpour Y, Jain S, Blinder S, Klyuzhin I, Smith G . Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. Neuroimage Clin. 2016; 12:e1-e9. PMC: 5153560. DOI: 10.1016/j.nicl.2016.02.012. View

12.

Takahashi M, Fujita M, Asai N, Saki M, Mori A . Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2018; 19(15):1635-1642. DOI: 10.1080/14656566.2018.1518433. View

13.

Ahlskog J, Muenter M . Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001; 16(3):448-58. DOI: 10.1002/mds.1090. View

14.

Fiorenzato E, Antonini A, Bisiacchi P, Weis L, Biundo R . Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease. Mov Disord. 2021; 36(10):2303-2313. PMC: 8596815. DOI: 10.1002/mds.28682. View

15.

Cilia R, Akpalu A, Sarfo F, Cham M, Amboni M, Cereda E . The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain. 2014; 137(Pt 10):2731-42. PMC: 4163032. DOI: 10.1093/brain/awu195. View

16.

Fernandez H, Greeley D, Zweig R, Wojcieszek J, Mori A, Sussman N . Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2009; 16(1):16-20. DOI: 10.1016/j.parkreldis.2009.06.008. View

17.

Aradi S, Hauser R . Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics. 2020; 17(4):1339-1365. PMC: 7851275. DOI: 10.1007/s13311-020-00889-4. View

18.

Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira A, Emre M . Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord. 2013; 28(8):1064-71. DOI: 10.1002/mds.25364. View

19.

Mori A . How do adenosine A receptors regulate motor function?. Parkinsonism Relat Disord. 2020; 80 Suppl 1:S13-S20. DOI: 10.1016/j.parkreldis.2020.09.025. View

20.

Hely M, Morris J, Reid W, Trafficante R . Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2004; 20(2):190-9. DOI: 10.1002/mds.20324. View